Danaher Is Poised For 'A Good Year In Bioprocessing': Analyst
Portfolio Pulse from Priya Nigam
Danaher Corp (NYSE:DHR) is expected to have a gradual recovery in 2025, with high-single-digit growth in the long term, according to Stifel analyst Jacob Johnson. The company, now a pure-play life sciences tools company, has faced recent headwinds but is poised for a good year in bioprocessing.
October 01, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Danaher Corp is expected to recover gradually in 2025, with high-single-digit growth in the long term. Analyst Jacob Johnson gives an Overweight rating and a $315 price target, highlighting the company's focus on life sciences and bioprocessing.
The analyst's Overweight rating and positive outlook for Danaher's recovery in 2025, along with a specific price target, suggest a positive short-term impact on the stock. The company's focus on life sciences and bioprocessing, areas with higher growth potential, supports this positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100